Traditional cancer care often relies on generalized treatment protocols that overlook the unique biology of each tumor. As a result, patients face:
CertaPath Drug Sensitivity Testing (DST) is an ex vivo screen that uses a patient’s own tumor tissue to guide personalized treatment decisions.
It gives oncologists clear data on which FDA-approved therapies show real activity against that patient’s tumor, helping them choose the options with the highest likelihood of success.
